Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Integrin chatter and vascular function in diabetic retinopathy

K T Preissner1, S M Kanse, H P Hammes

  • 1Haemostasis Research Unit, Kerckhoff Klinik, MPI, Bad Nauheim, Germany.

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|March 14, 1998
PubMed
Summary

Integrin antagonists show promise for treating diabetic retinopathy by reducing abnormal blood vessel growth. This therapy targets advanced glycation end products that disrupt retinal cell interactions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calafiore cardioplegia offers better myocardial protection in adult and senescent rat hearts than Del Nido cardioplegia.

Perfusion·2023
Same author

Carnosinase Gene-Is It Responsible for Diabetic Nephropathy?: Carnosine as a Protective Factor in Diabetic Nephropathy: Association with a Leucine Repeat of the Carnosinase Gene CNDP1. Diabetes 54: 2320-2327, 2005.

Journal of the American Society of Nephrology : JASN·2023
Same author

Genome-wide analysis of genetic determinants of circulating factor VII-activating protease (FSAP) activity.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Hamostaseologie·2018
Same author

Factor VII activating protease.

Hamostaseologie·2018
Same author

Factor VII-activating protease deficiency promotes neointima formation by enhancing leukocyte accumulation.

Journal of thrombosis and haemostasis : JTH·2016

Area of Science:

  • Vascular biology and pathophysiology
  • Ophthalmology
  • Diabetic complications

Background:

  • Cell adhesion receptors and proteolytic enzymes are vital for vascular cell functions.
  • Advanced glycation end products disrupt endothelial-extracellular matrix interactions in diabetic retinopathy.
  • Vitronectin receptor-type integrins on angiogenic endothelial cells promote retinal neovascularization.

Purpose of the Study:

  • To investigate the role of integrins in hypoxia-induced retinal neovascularization.
  • To evaluate the efficacy of integrin antagonists as an angiostatic therapy for diabetic retinopathy.

Main Methods:

  • Utilized a hypoxia-induced retinal neovascularization mouse model.
  • Administered low molecular weight integrin antagonists.

Related Experiment Videos

  • Assessed the impact on unwanted angiogenesis.

    • Main Results:

    • Low molecular weight integrin antagonists significantly reduced unwanted angiogenesis in the retinal neovascularization model.
    • Demonstrated the potential of integrin antagonism as an angiostatic strategy.

    Conclusions:

    • Integrin antagonism is a promising therapeutic approach for managing aberrant angiogenesis in diabetic retinopathy.
    • This therapy may offer a novel treatment for advanced diabetic eye disease complications.